↓ Skip to main content

Dove Medical Press

Article Metrics

Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer

Overview of attention for article published in Drug Design, Development and Therapy, January 2012
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (68th percentile)
  • Above-average Attention Score compared to outputs of the same age and source (60th percentile)

Mentioned by

twitter
1 tweeter
wikipedia
1 Wikipedia page

Citations

dimensions_citation
68 Dimensions

Readers on

mendeley
103 Mendeley
Title
Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer
Published in
Drug Design, Development and Therapy, January 2012
DOI 10.2147/dddt.s15850
Pubmed ID
Authors

Yasser Rehman, Yasser Rehman

Abstract

Prostate cancer is the second leading cause of cancer death in men in the US and Europe. The treatment of advanced-stage prostate cancer has been androgen deprivation. Medical castration leads to decreased production of testosterone and dihydrotestosterone by the testes, but adrenal glands and even prostate cancer tissue continue to produce androgens, which eventually leads to continued prostate cancer growth despite castrate level of androgens. This stage is known as castrate-resistant prostate cancer (CRPC), which continues to be a challenge to treat. Addition of androgen antagonists to hormonal deprivation has been successful in lowering the prostate-specific antigen levels further, but has not actually translated into life-prolonging options. The results of several contemporary studies have continued to demonstrate activation of the androgen receptor as being the key factor in the continued growth of prostate cancer. Blockade of androgen production by nongonadal sources has led to clinical benefit in this setting. One such agent is abiraterone acetate, which significantly reduces androgen production by blocking the enzyme, cytochrome P450 17 alpha-hydroxylase (CYP17). This has provided physicians with another treatment option for patients with CRPC. The landscape for prostate cancer treatment has changed with the approval of cabazitaxel, sipuleucel-T and abiraterone. Here we provide an overview of abiraterone acetate, its mechanism of action, and its potential place for therapy in CRPC.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 103 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Israel 1 <1%
Germany 1 <1%
Canada 1 <1%
Unknown 100 97%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 20 19%
Student > Master 19 18%
Student > Bachelor 15 15%
Researcher 14 14%
Other 7 7%
Other 18 17%
Unknown 10 10%
Readers by discipline Count As %
Medicine and Dentistry 34 33%
Agricultural and Biological Sciences 16 16%
Biochemistry, Genetics and Molecular Biology 11 11%
Pharmacology, Toxicology and Pharmaceutical Science 10 10%
Chemistry 7 7%
Other 11 11%
Unknown 14 14%

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 September 2018.
All research outputs
#6,277,197
of 20,710,163 outputs
Outputs from Drug Design, Development and Therapy
#395
of 1,922 outputs
Outputs of similar age
#42,363
of 141,926 outputs
Outputs of similar age from Drug Design, Development and Therapy
#5
of 10 outputs
Altmetric has tracked 20,710,163 research outputs across all sources so far. This one has received more attention than most of these and is in the 68th percentile.
So far Altmetric has tracked 1,922 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.5. This one has done well, scoring higher than 78% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 141,926 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 68% of its contemporaries.
We're also able to compare this research output to 10 others from the same source and published within six weeks on either side of this one. This one has scored higher than 5 of them.